Which generation of drug is entrectinib? How does it compare to other targeted drugs?

Entrectinib is a third-generation targeted drug mainly used to treat NTRK gene fusion-positive tumors. It is a tyrosine kinase inhibitor (TKI) that prevents the proliferation and spread of tumor cells by targeting and inhibiting the activity of TRK receptors. Entrectinib is unique in that it targets a variety of tumor types carrying NTRK gene fusions and can effectively treat tumors in a variety of different locations, including non-small cell lung cancer, breast cancer and other NTRK-positive solid tumors. As a third-generation drug, entrectinib can not only combat resistance to early drugs, but also achieve significant efficacy in multiple tumor types.

Entrectinib has obvious advantages over first- and second-generation TKI targeted drugs. First- and second-generation TKIs usually only target specific mutation types (such as EGFR or ALK mutations), while entrectinib is a broad-spectrum targeted drug that can simultaneously inhibit a variety of tumors with NTRK gene fusions. NTRK fusion genes occur in many different types of cancer, and these tumors are often difficult to control with traditional treatments. The broad-spectrum targeting effect of entrectinib gives it great advantages in the treatment of these specific tumors, especially in patients with large tumor heterogeneity.

Compared with traditional EGFR and ALK inhibitors, entrectinib has greater ability to cross the blood-brain barrier. Some targeted drugs, such as osimertinib, although effective in targeting specific mutations, have limited therapeutic effect on brain metastases. Entrectinib shows strong advantages in this regard, being able to effectively penetrate the blood-brain barrier and exert a therapeutic effect on brain metastases. Therefore, entrectinib has become one of the ideal choices for the treatment of patients with brain metastases, which provides an important treatment option for some NTRK gene fusion-positive patients with brain metastases.
In terms of side effects, the side effects of entrectinib are relatively mild, and most side effects are reversible. Common side effects include fatigue, nausea, loss of appetite, and weight loss, but these are mild in most patients and can be managed with medication dose adjustments or symptomatic treatment. Compared with other targeted drugs, entrectinib has a lower incidence of side effects and is better tolerated by patients. In addition, entrectinib has shown long-term efficacy and drug resistance control in clinical trials, bringing more treatment hope to patients.
Reference: https://www.roche.com/products/rozlytrek